PTGS2 and non-small cell lung carcinoma: More recently, the TZDs pioglitazone and rosiglitazone have been shown to inhibit PGE2 production in NSCLC cells via a COX-2 independent pathway by upregulation of 15-hydroxyprostaglandin dehydrogenase [52].